Member Info for Teamhanz

Nice 5-10% daily increases until the Q&A end of the week im thinking. Would be Nice. Then come December much of the same. 40p before the results is where i think we should be now already.

Wouldn't the full details be posted under 201 on clinicaltrial.gov straight after the RNS Grace?

sounds like an organised pump?

Well if you had your finger on the pulse you would know its a whole new management team, strategy etc so you could get what you are hoping for. 301 being reviewed, 201 full results due in Q4. Lots to look forward too.

hahaha RB literally just spat my tea out reading that!

If only! That would be nice

Thanks Adam for your thoughts, views and views insights. Very much appreciated.

Adam, purely speculative, but if the Japanese were happy with what they found and they opted for a upfront/ milestones etc, at preclinical stage, what is your personal opinion would be a fair deal for an upfront payment and what stages and money would you expect to see in milestone payments? Kid Regards as always.

strange all those 100 share trades?

Thanks Adam. Always appreciate your posts/views and help.

Thanks bud. thought it must be that but seeing as you are such a decent chap knew you would clear that up. ATB and fingers crossed the tide has now turned.

RB, not knowing much about L2. Can i ask what 2v1 and 10kv5k means in laymans terms? thanks

Are these full clinical trials though? The Japanese Pharma are doing in house preclinical

leaky leaky that results are about to be released or the Japanese are ready to show their hand?

Look forward to reading it Grace :-)

Hopefully here we go!!!!

Well this is horrendous! A drop from the 60s and its still dropping. Such fun.

Bored, doing a bit of digging etc and when you look on Valirxs website under 201, it names a H. Yamaguchi...shot in the dark. Could it be - Hideto Yamaguchi Vice President, Chemical & Biological Technology Labs at Astellas Pharma Inc.? That would be very interesting.

LSE down pretty much all day. Joke. Quite the battering today.

For me this was the most valuable part was this - Evaluation of VAL301 by a potential partner nearing conclusion: An undisclosed
Japanese company is currently evaluating VAL301, the Group’s preclinical stage
treatment candidate for endometriosis, a common gynaecological condition.
Should the evaluation be successful, there is potential for an agreement to be struck
regarding VAL301. This may take the form of a full development license agreement,
with upfront payments and royalties, or a co-development agreement through a JV.

Nearing conclusion. That is the first time that has been said.